Harbour BioMed Appoints Ms. Vivian Feng as Head of External Collaboration

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 5, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Ms. Vivian Feng as Senior Vice President, Head of External Collaboration. Ms. Feng will be based in Shanghai and report directly to Mike Patten, Chief Strategy Officer of Harbour BioMed.

In this role, Ms. Feng will be responsible for leading and shaping Harbour BioMed's external collaboration strategy, connecting the Company's platform, pipeline, and innovation capabilities with partners to drive long-term corporate growth and value creation. She will oversee business development and licensing activities across the HBM Group, foster synergy and information flow across its entities and NewCos, and build the processes and team capabilities required for a scalable, risk-controlled external collaboration function.

Ms. Feng brings over 16 years of end-to-end biotech and pharma business development experience, spanning global licensing in and out, M&A, and equity investment. Most recently, she served as General Manager of the Business Development Department at Fosun Pharma, where she led global business development initiatives and established a comprehensive group-level BD system covering valuation, due diligence, and risk control.

Prior to Fosun Pharma, Ms. Feng held business development leadership roles at Besins Healthcare Shanghai Limited, Shanghai Tenry Pharmaceutical Group, and Shanghai Newsummit Pharmaceutical Group, where she successfully executed international out-licensing, co-development projects, and over 100 product/asset evaluations.